Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Jun 27, 2024 Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare Photos 1 Jun 11, 2024 Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter May 15, 2024 Evofem Biosciences Announces Financial Results for the First Quarter of 2024 Apr 18, 2024 Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO Mar 27, 2024 Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 Mar 20, 2024 Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal Mar 7, 2024 For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy Feb 1, 2024 Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Jan 8, 2024 Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game Dec 12, 2023 Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally Show 5102550100 per page«123456789…24»
